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Abstract  
Title: Models used for case-mix adjustment of patient reported outcome measures (PROMs) in 
musculoskeletal healthcare: A systematic review of the literature. 
Background: Case-mix adjustment is an established method to take account of variations 
across cohorts in baseline patient factors, when comparing health outcomes. Although 
commonplace, there is a lack of evidence as to the most appropriate case-mix adjustment 
model to use to enable fair comparisons of PROM data in musculoskeletal services.  
Objectives: To conduct a systematic review summarising evidence of the development, 
validation, and performance of musculoskeletal case-mix adjustment models, and to make 
recommendations for future methods. 
Data Sources: Searches included; AMED, CINAHL, EMBASE, HMIC, MEDLINE, and grey 
literature.  
Eligibility Criteria: Studies; from January 1992-May 2017, English language, musculoskeletal 
adult population, developing or validating a case-mix adjustment model, using a relevant 
PROM, and using patient factors feasible for clinical collection.  
Data Synthesis: Two reviewers evaluated selected papers. The CASP Cohort Tool was used 
to assess quality.  
Results: Fourteen studies were included; eight US studies on the Focus on Therapeutic 
Outcomes model (pooled n=546,726 patients (with pre/post treatment data)) and six UK 
studies related to the UK National PROMs Programme model (pooled n=282,424 patients 
(with pre/post treatment data)). The majority used retrospective data, restricted to 
complete datasets. Both US and UK models showed good predictive ability (R2 18-42%). 
Common model variables were; baseline PROM score, age, sex, comorbidities, symptom 
duration, and surgical history. Reduced quality scores were mainly due to acceptability of 
patient recruitment, and completeness and length of patient follow up. 
Conclusion: Significant methodological crossover was found. Further studies are however 
needed to externally validate and develop models across musculoskeletal settings.   
Contribution of the Paper: 
 This systematic review has identified two broad musculoskeletal case-mix adjustment 
models, and highlights both the commonalities in case-mix adjustment approaches but also 
the need for further good quality studies to inform future practice.  
 Effective case-mix adjustment modelling across musculoskeletal clinical pathways of care 
will allow for further development of performance profiling and benchmarking across 
musculoskeletal practice, with the aim of improving quality and equity of musculoskeletal 
healthcare provision.  
Key words: case-mix adjustment model, musculoskeletal, patient outcomes, PROM. 
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Introduction  1 
Routine use of patient reported outcome measures (PROMs) can help patients and clinicians make 2 
better decisions, and enable comparisons of providers’ performance facilitating quality improvement 3 
[1]. For example, the UK National PROMs Programme has successfully raised standards in the area of 4 
hip and knee replacement surgery [2]. Patient outcomes are a function of; therapeutic intervention 5 
effectiveness, quality of care, patient attributes that affect their response to care (e.g. ‘risk factors’), 6 
the natural course of a condition and random chance, [3, 4]). Case-mix or risk adjustment (termed 7 
case-mix adjustment here for consistency) is a statistical process that aims to account for differences 8 
in the mix of patient attributes across definitive patient cohorts, in order to make fair comparisons 9 
of the relative effectiveness (outcome) of care provided [3]. For example to enable fair comparisons 10 
across different musculoskeletal physiotherapy services  it may be appropriate to adjust for 11 
population differences in age or symptom duration, as these are known to influence patient 12 
outcomes following treatment [5]. Other known patient factors that influence musculoskeletal 13 
treatment outcomes include; gender, symptom severity, and impairment type [6].These patient 14 
factors are beyond the control of the treatment provider, unlike provider factors such as the waiting 15 
time, clinic setting, or treating clinician, which also influence treatment outcomes [7]. Case-mix 16 
adjustment aims to avoid inclusion of  provider variables as these variables could remove effects 17 
that may be attributable to local quality improvement  initiatives, and potentially can adjust out the 18 
differences in quality and performance that are being investigated [8]. For example, if one 19 
physiotherapy service had treating clinicians of a much higher grade than another, and grade of 20 
therapist was adjusted for when examining their respective treatment outcomes, then any variation 21 
due to the differing skill-mix between the services would be adjusted out rather than being used to 22 
help explain the differences and inform quality improvement initiatives. Most case-mix models 23 
therefore only adjust for patient factors to allow for fair inter provider comparisons [8].  24 
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Within a musculoskeletal context the evidence for case-mix adjustment models to compare inter 25 
provider treatment outcomes has not been systematically evaluated, and there has been no 26 
previous review of the literature to the authors’ knowledge. This review therefore aims to 27 
summarise the evidence for the development, validation, and performance of musculoskeletal case-28 
mix adjustment models, and make recommendations for future case-mix adjustment methodology. 29 
Methods 30 
This review followed protocol guidance set out within the PRISMA statement [9], and has been 31 
registered on the PROSPERO database (CRD42017055948). 32 
Eligibility Criteria: Inclusion criteria were: studies from January 1992 to May 2017 (in line with early 33 
implementers of musculoskeletal PROM collection [10] and to provide currency and applicability of 34 
results), English language studies (due to resource limits), observational cohort studies, adult 35 
patients seeking treatment for musculoskeletal conditions, use of a case-mix adjustment model 36 
(focus on development, refinement or validation), self-reported treatment outcomes at a follow-up 37 
time-point (capturing treatment effect/change), and models adjusting PROMs and including 38 
variables feasible for widespread collection (not using variables such as imaging results that are not 39 
uniformly collected). Exclusions were: studies not reporting detailed results, and those not reporting 40 
statistical model effectiveness.  41 
Searches: A search strategy was developed iteratively with guidance from an experienced systematic 42 
reviewer, initially conducting test searches for a single database until the refined strategy was 43 
agreed that amalgamated sets of search terms, reduced individual terms, and exploded  terms such 44 
as ‘musculoskeletal’ to optimise the balance between search sensitivity and precision [11]. Search-45 
terms included key words for; target population, musculoskeletal conditions, outcomes, and 46 
methodology.  Electronic databases searched were: CINAHL, MEDLINE, EMBASE, AMED and HMIC 47 
(see Appendix 1 for search strategy (MEDLINE)) from January 1992 to May 2017. Grey literature 48 
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included searches of NHS Evidence websites of the Department of Health [12] and NICE [13]. 49 
Additional searches included references and citations of included studies. Seminal authors/research 50 
groups were also contacted for all identified case-mix models to ensure latest iterations were 51 
included and to identify any additional models.  52 
Selection Process: One independent reviewer (RB) undertook a preliminary screen of all titles to 53 
remove studies clearly and unquestionably excluded from the study. RB then screened all remaining 54 
abstracts identified from searches alongside a second reviewer (AB or JH). Two independent 55 
reviewers (RB and JH or AB or ML) then read full articles identified to confirm they met the inclusion 56 
criteria.   57 
Data Extraction and Quality Assessment: Information on identified articles was independently 58 
entered onto a data extraction form by the two reviewers, with the form reflecting the key themes 59 
from the STROBE Checklist [14], and quality assessed using the CASP Cohort Quality Tool [15]. 60 
Agreement on study inclusion was first discussed between two reviewers. As there were no disputed 61 
studies discussion for agreement between all reviewers was not required.  62 
A systematic narrative synthesis was conducted, with information presented in table and text format 63 
to summarise and explain the history and development of identified case-mix adjustment models, 64 
and the overall study findings. A meta-analysis pooling the study data was not possible due to the 65 
large methodological diversity (heterogeneity) among studies [11] in patient factors and statistical 66 
methods used. For this reason, results were summarised in tables and discussed in detail. Each case-67 
mix adjustment model and their associated studies/papers and statistical methods were presented 68 
together for ease of viewing overarching findings. 69 
Results 70 
Search Results: Electronic database searches identified 755 articles for consideration with 517 71 
remaining after duplicate removal (see Figure 1). Grey literature and additional searching identified 72 
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a further 12 articles. All seven experts (or alternative experts from their research group) responded 73 
and this identified one additional manuscript that was being prepared for submission that was 74 
unable to be included within the review. Following screening, fourteen articles were included (see 75 
Figure 1). Two broad case-mix adjustment models were identified; US Focus on Therapeutic 76 
Outcomes (FOTO), and UK National PROMs (NPROMs)). 77 
Figure 1: Flowchart of Search Results 78 
Eight of the fourteen studies included were undertaken in the US, using data from the FOTO 79 
database [5, 6, 16, 17, 18, 19, 16, 17], with four of those authored (primary author) by members of 80 
the FOTO Research Advisory Board (FRAB) [5, 6, 17, 20]. The other four were independently led and 81 
given access to the FOTO database [16, 18, 19, 21] although two of them were also co-authored by 82 
FRAB members [16, 18]. Included study sample sizes ranged from n = 323 [17] to n = 189,088 [5]. 83 
The pooled sample size across US studies with pre and post treatment data was 546,726. 84 
Six of the fourteen included studies were UK based. These included feasibility work for the NHS 85 
England NPROMs Programme [22], NPROMs publications [8, 23, 24], and independent researchers 86 
using NPROMs data [25, 26]. All of these studies were only identified following review of the grey 87 
literature/additional searches as they were all NHS publications or secondary analyses of NHS data. 88 
Included study sample sizes ranged from n = 387 [22] to NPROMs data which increased yearly from; 89 
2009-10 (n=85,177), 2010-11 (n=95,406), 2011-12 (n=101,454) totalling 282,037 patients [23, 24]. 90 
The pooled sample size across UK studies with pre and post treatment data was 282,424.  91 
Follow up was standardised at six months across UK studies but was non-standardised in US FOTO 92 
studies with collection at the end of the treatment episode. All included studies were cohort studies, 93 
with three prospectively collecting data [8, 18, 22], and the rest undertaking retrospective analyses 94 
of existing datasets.  For results detail see Table 1 for quality of included studies, Table 2 for 95 
summary of articles included, and Table 3 for summary of model variables within included studies. 96 
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Quality Appraisal: The CASP quality evaluation found that studies were of a good quality (see Table 97 
1). There were however consistent sources of bias across studies within identified areas such as 98 
patient recruitment and completeness of follow up, which are discussed below.  99 
Key sources of bias across US studies included: Selection-bias due to the exclusion of a large 100 
percentage of participants with missing data (see Table 1). Hart et al [17] for example were only able 101 
to include 323 of 39,529 patients (0.8%) within their routine dataset as only these patients had data 102 
for all psychosocial measures pertinent to the study, as collecting multiple psychological measures 103 
was not routine practice. This, however, may have biased their sample to those more likely to be 104 
psychologically impaired (as acknowledged by the authors). Three of the eight US studies did 105 
however use inverse probability weighting to account for missing data [18, 19, 21]. Four studies 106 
compared baseline characteristics between those with missing and complete data to assess 107 
likelihood of bias, broadly concluding that although some differences were found these were 108 
unlikely to lead to systematic selection biases as missing data included both patients with 109 
characteristics associated with better and worse outcome [5, 6, 17, 20]. Patients were however also 110 
limited to those attending clinics using FOTO software so may not be representative of clinics across 111 
the US (n=4776 clinics currently across the US [10]). All US studies had non-standardised follow-up 112 
outcome assessment time-points with collection at the completion of the individual’s treatment 113 
episode, both preventing the collection of follow up data for those who ceased attending for 114 
treatment and limiting the ability to quantify estimates of efficacy for a given time. Patients with 115 
missing follow up data may therefore be ‘missing not at random’ [27] having chosen to cease 116 
attending leading to further potential attrition bias [11]. Resnik and Hart [16] reported that these 117 
patients were younger and had higher functional status scores and therefore hypothesised that they 118 
were likely to have ceased attending due to resolution of their symptoms. However, not including 119 
those with greater chances of improvement as well as the variation in outcome collection timing 120 
could substantially impact on the case-mix models and their reported predictive abilities [28].   121 
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Key sources of bias across UK studies included: Selection-bias due to the exclusion of those with 122 
missing data (see Table 1). The study by Browne et al [22] used the SF-36 rule [29] for dealing with 123 
missing data, but 25% of eligible patients were excluded due to failure to invite these patients to 124 
participate. Due to data linkage between data sources within the NPROMs Programme, unlinked 125 
data were also not able to be included in the full analysis, which could again have potentially biased 126 
the final patient sample. In 2011/12 116,734 of 247,699 patients who underwent PROMs eligible 127 
procedures had complete and linked data (47.13%), this was 63.1% of those who completed baseline 128 
PROM data [30]. Whether this impacted on results would depend on whether unlinked or missing 129 
data was missing at random [27] or whether this was due to systematic poor administrative 130 
processes at certain provider NHS trusts, which is unclear. Follow-up data collection across UK 131 
studies was standardised at a six month time-point although baseline data collection occurred both 132 
at pre admission clinics and at admission for the surgical procedure, leading to a small source of 133 
variation.  134 
All included studies used data from clinical databases and were therefore impacted by limitations in 135 
controlling the quality of the data and rates of attrition. Most studies reported these limitations 136 
reinforcing the issues around the use of clinical data for research purposes. However although 137 
acknowledged, these limitations led to a high risk of bias for this domain within included studies 138 
[11].  139 
Table 1: Quality Assessment using CASP Cohort Tool 140 
Table 2: Summary of Included Studies 141 
Table 3: Summary of Case-mix Adjustment Model Variables 142 
Model development history:  143 
US Model: Early FOTO models made case-mix adjustments using 12 baseline variables as 144 
demonstrated by Hart and Connolly [6] (see Table 3) that were found to have a significant effect on 145 
7 
 
discharge functional status (FS). This model predicted 35% of total variance, meaning that 35% of the 146 
variance in post treatment outcome could be explained by the model. The three most important 147 
patient factors in their model were; baseline FS, age and symptom duration [6], supporting work 148 
from Resnik and Hart [16]. FOTO Inc. later moved to a case-mix adjustment model with eight patient 149 
factors, aware of the need to balance model performance with data collection feasibility [6], as 150 
demonstrated in the paper by Hart et al [5], who looked at the benefit of adding fear avoidance 151 
beliefs (FABQ-PA) to the model. Their results demonstrated R2 values of 0.2997 and 0.3010 152 
respectively, with and without the inclusion of the FABQ-PA, thus improving model predictive ability 153 
but only slightly, and therefore not recommending this variable for model inclusion.  154 
UK Model: In 2007 Browne et al [22], set out to determine the feasibility of collecting pre and post-155 
operative outcome data from patients undergoing elective surgery, and to develop methods to 156 
analyse and present the pooled data from different hospitals. Elective surgeries included five areas, 157 
with two of musculoskeletal interest: unilateral hip replacement and unilateral knee replacement. 158 
Significant variables within their case-mix adjustment models were baseline PROM score, 159 
comorbidities, general health, surgical history, age, and Index of Multiple Deprivation (IMD). Models 160 
explained between 24% and 27% of total variance in treatment outcome.  161 
Following the feasibility work by Browne et al [22], Coles [8] published the full UK NPROMs case-mix 162 
adjustment methodology (see Table 3 for list of variables). Coles [8] describes six orthopaedic 163 
models (separate models for each PROM used and for each intervention). Models ranged from 16-20 164 
included variables and explained between 23% and 30% of total variance. All models found the 165 
patient’s baseline score to be highly predictive of outcome, as well as IMD, comorbidities, patients 166 
reporting themselves free of a disability (positive impact), and general health.  167 
In 2011 increased data was available from the NPROMs collection which aided further model 168 
refinement, including changing the variables relating to co-morbidities and then removing general 169 
health [23]. Key predictive variables within the updated model were baseline PROM score, disability 170 
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status, comorbidity of depression, patient needing assistance with questionnaire, and IMD [23]. In 171 
2013, an alternative aggregation model (AAM) was proposed by NHS England [31], to further 172 
improve model stability. The full model was also updated following the separation out of primary 173 
and revision surgery (giving less prediction error). Significant model changes included removing the 174 
previous surgery variable and inclusion of some additional patient diagnostic codes. Key variables 175 
predicting outcome across updated primary hip and knee models were; baseline PROM score, age, 176 
sex, assistance with questionnaire, disability status, comorbidities, ethnicity, diagnostic codes, and 177 
IMD [24].  178 
Model validation: 179 
US Model: Hart and Connolly [6] used two methods to validate the FOTO case-mix adjustment 180 
model. The patient sample was split into two, one to develop the model and one to test the stability 181 
of independent variables. 95% confidence intervals for the beta coefficients for all case-mix 182 
adjustment variables were similar. In the development sample the predicted discharge FS was very 183 
close to the actual discharge FS (average predictive ratio 1.045), although the model slightly over 184 
predicted FS in the second testing sample. The paper by Hart et al [5] also carried out a split-half 185 
validation method to create a developmental and testing sample. No differences were found 186 
between beta coefficients between developmental and testing samples (p<0.05), again suggesting 187 
stability within the predictive model [5].  188 
UK Model: The inception NPROMs paper [8] considered the face validity of the case-mix adjustment 189 
models, appropriateness of scale, and direction and stability of the coefficients.  The developed 190 
model was then tested in a subset of data. Comparisons between datasets and early testing 191 
suggested scope for removal of further variables either due to low incidence or volatility. The model 192 
for Knee surgery using EQ5D VAS as the outcome showed the only significant difference in samples. 193 
This was due to the low incidence of some comorbidities, and lack of specific admission and 194 
discharge data.  All models showed face validity containing appropriate variables with directionally 195 
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expected coefficients. Nuttall et al [26] independently reviewed case-mix adjustment of NPROMs 196 
data. Mean predicted post-operative scores and mean actual scores were compared using three 197 
statistical methods (ordinary least squares (OLS), fixed effects (FE), and random effects (RE) models). 198 
They demonstrated that a fixed effects (FE) model performed the best [26].  199 
Model statistical methods: The majority of studies used a stepwise approach when building a new 200 
regression model in order to make the most parsimonious model for clinical practice, and used 201 
specific significance levels (0.05 [6], 0.1 [20] and 0.15 [8]) for inclusion/exclusion of independent 202 
explanatory variables.  Early US and UK models used an ordinary least squares (OLS) multivariate 203 
regression method to estimate model power (R2) [6, 8]. Hierarchical models were demonstrated in 204 
later papers [19, 21, 27]. UK NPROMs moved to the use of a generalised least squares (GLS) method 205 
in 2011 [23]. Support is growing for the use of GLS [23, 26] and hierarchical mixed models [19] that 206 
take into account the nature and distribution of the data, including random clinic effects such as 207 
clustering (unmeasured factors within clinics that may affect outcome). The majority of latter papers 208 
therefore include using a stepwise approach to model development, and a GLS or hierarchical model 209 
for statistical analysis.  210 
Model predictive abilities: Using regression analysis, goodness of fit can be found by calculating R2 211 
which is usually expressed as a percentage. It explains the percentage of the variation in the 212 
dependent variable (PROM score) that can be explained by its relationship with the independent 213 
variables (patient factors) [32]. Predictive ability across US study models ranged from 18-42% [5, 6, 214 
16, 17, 18, 19, 20) and in UK models from 23-30% [8, 22, 26], demonstrating moderate to strong 215 
predictive ability across models [33]. 216 
Discussion: 217 
Table 3 details the patient factor variables used most commonly (those used in 3 or more studies) in 218 
included case-mix adjustment models. It can be seen that the most widely used variables across 219 
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models predicting outcome include: baseline PROM score, comorbidities, surgical history, IMD, age, 220 
payer, symptom duration, impairment type, assistance with questionnaire, self-reported disability, 221 
gender, and ethnicity. All of these variables are feasible for widespread clinical collection and 222 
warrant being considered for inclusion in future musculoskeletal case-mix adjustment modelling.  223 
Variables such as exercise history, living alone, FABQ, use of medication, and pain intensity had some 224 
limited support but require further investigation before their inclusion can be fully justified. All US 225 
studies used the payer variable and all UK studies used the IMD, these two variables may measure a 226 
similar construct as payer types have been used as proxy measures for a variety of demographic 227 
factors [19, 34].  228 
Although there is considerable crossover in variables included within models, there is wide disparity 229 
in how variables are collated and entered into regression models, with a mixture of continuous, 230 
categorical and binary data. Models also used different outcome tools and different timing of follow-231 
up data collection. This would need to be considered when looking to test, replicate or build upon 232 
existing case-mix adjustment models, as when and how predictors and treatment outcomes are 233 
measured can have significant effects on model predictive performance [28]. 234 
Limitations of the review: The review focussed on the case-mix adjustment of musculoskeletal 235 
PROM data. However, the outcome used within studies was not limited and therefore studies and 236 
the predictive performance of models identified cannot be fully compared. Evidence from the UK 237 
NPROMs research demonstrates that different variables are necessary dependent on the outcome 238 
used [8, 24]. The review also included all healthcare settings including primary, community and 239 
secondary care. The limitation of this breadth is again the comparability of included studies, as 240 
patients, treatments and outcomes across settings all vary significantly. The review was also limited 241 
to English language publications meaning that there may be models reported in languages other 242 
than English that have not been included.      243 
Summary of findings: 244 
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Two broad case-mix adjustment models have been identified within the review. Neither model 245 
however has been externally validated.  The two models are distinct in that one model is currently 246 
used within a community setting in the US (FOTO), and the other in a UK secondary care surgical 247 
setting (NPROMs). Future research is needed to externally validate these existing models within and 248 
across musculoskeletal settings and countries, in order to be able to implement these models across 249 
healthcare settings. 250 
Recommendations for future case-mix adjustment modelling of musculoskeletal PROMs based on 251 
the combined study findings are: 252 
1. Patient factor variables warranting strong consideration for inclusion are: baseline PROM 253 
score, age, gender, comorbidities, symptom duration, surgical history, payer, impairment 254 
type, IMD, ethnicity, assistance with questionnaire, and self-reported disability. 255 
2. A stepwise approach to model development is recommended, with significance levels of 256 
0.05-0.15 demonstrated within included studies [6, 8, 20]. 257 
3. Statistical methods for consideration include GLS and hierarchical modelling which may be 258 
preferential to an OLS method due to accounting for clustering.  259 
4. Methods need to minimise or account for missing data using structured prospective data 260 
collection and statistical methods such as data imputation or inverse probability weighting. 261 
5. Defined PROM data capture at the start and end of treatment with a standardised follow up 262 
time-point is recommended to reduce risk of bias. 263 
 264 
Conclusion: 265 
Results demonstrate that there is strong evidence to support the use of case-mix adjustment 266 
modelling in musculoskeletal practice, and results highlight common areas of overlap between US 267 
and UK models, and models used within a community and secondary care setting. These results have 268 
been summarised to aid development of case-mix adjustment methodology alongside much needed 269 
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external validation of existing models, with the aim of optimising case-mix adjustment of 270 
musculoskeletal health outcomes. This will allow for effective performance profiling and future 271 
benchmarking of musculoskeletal services, both nationally and internationally.   272 
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 277 
755 records identified through 
electronic database searching 
(CINAHL, MEDLINE, 
EMBASE, AMED, HMIC)  
12 additional records 
identified through other sources 
(grey literature/reference 
lists/citation tracker) 
529 records after duplicates removed 
529 records screened 500 of records excluded 
29 full-text articles 
assessed for eligibility 
14 studies included in qualitative 
synthesis 
8 US studies  
Gozalo 2016 [21] 
Hart 2006 [6] 
Hart 2011[5] 
Hart 2011[17] 
Resnik 2003 [16] 
Resnik 2011 [18] 
Werneke 2016 [20] 
Yen, 2015 [19] 
6 UK studies 
Browne 2007 [22] 
Coles 2010 [8]  
Gutacker 2012 [25] 
NHS England 2012 [23] 
NHS England 2013 [24] 
Nuttall 2015 [26] 
15 full-text articles excluded, 
with reasons: 
- Case-mix adjustment 
not focus:  
Childs 2014 [35]  
Deutscher 2014 [36]  
Gomez 2014 [27] 
Judge 2012 [37]  
Resnik 2008 [38] 
Rodeghero 2015 [39]  
Schafer 2010 [40]  
Werneke 2008 [41], 
2009 [42], 2011[43,44] 
- PROM not pre and 
post treatment:  
Braeken 1997[45] 
Fanuele 2000[46] 
- No PROM:  
Grigsby 2001[47] 
- Focus on method not 
model: 
NHS England 2013 [31] 
 
0 studies included in quantitative 
synthesis (meta-analysis) 
All studies in italics identified electronically  
Only first author stated in figure (see references for full detail) 
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Table 1: Quality Assessment Using CASP Cohort Tool 
 
 
 
 
Table 2: Summary of Included Studies 
CASP Cohort Tool
Author Clearly 
focussed
Recruit-
ment 
acceptable
Exposure 
accurately 
measured
Outcome 
accurately 
measured
Identified 
con-
founding
Accounted 
for con-
founding 
Subject 
FU 
complete 
enough
Subject 
FU long 
enough
Results 
Precise
Believe 
results
Applicable 
results
Fit with 
other 
evidence
Complete 
data
First Author US
Resnik 2003 [16] Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes
Hart 2006 [6] Yes CT Yes Yes Yes. Yes Yes Yes Yes CT No CT 62%
Hart 2011 [5] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 62%
Hart 2011 [17] Yes No Yes Yes Yes Yes No CT No Yes Yes CT 0.80%
Resnik 2011 [18] Yes No Yes Yes Yes Yes No CT Yes Yes Yes Yes 44.30%
Yen 2015 [19] Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Gozalo 2016 [21] Yes Yes Yes Yes Yes Yes No CT Yes Yes Yes Yes 57.20%
Werneke 2016 [20] Yes Yes Yes Yes Yes No No Yes Yes Yes Yes Yes 35%
First Author UK
Browne 2007 [22] Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes CT 90.2-91.6%
Coles 2010 [8] Yes CT Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
DoH 2012 [23] Yes CT Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
DoH 2013 [24] Yes CT Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Gutacker 2012 [25] Yes CT Yes Yes Yes No Yes Yes Yes Yes Yes Yes
Nuttall 2015 [26] No Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes 83.90%
(FU; fol low up, CT; Can't tel l )
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First Author/s Design Setting Data Sources Study Size 
(complete/included 
datasets) 
PROMs Number of 
variables 
Model R2 
(where 
available) 
US Studies        
Resnik and Hart 
(2003) [16] 
Retrospective 
cohort 
Outpatient 
physical therapy 
FOTO 24,276 OHS, SF-12, SF-
36 
8 35-42% 
Hart and Connolly 
(2006) [6] 
Retrospective 
cohort 
Outpatient 
therapy 
FOTO 189,088 FS 12 35-36% 
Hart (2011) [5] Retrospective 
cohort 
Outpatient 
therapy 
FOTO 49,376 FS 8 30% 
Hart (2011) [17] Prospective 
cohort 
Outpatient 
therapy 
FOTO 257 FS 10 (plus PM) 31% (intake 
model) 
Resnik (2011) [18] Prospective 
cohort 
Outpatient 
therapy 
FOTO 44,925 FS 8 18-40% 
Yen (2015) [19] Retrospective 
cohort 
Outpatient 
therapy 
FOTO 147,623 FS 7 31% (FE model) 
Werneke (2016) 
[20] 
Retrospective 
cohort 
Outpatient 
physical therapy 
FOTO 723 FS 13 (tested in 
BM) 
35% (BM) 
Gozalo (2016) [21] Retrospective 
cohort 
Outpatient 
therapy 
FOTO 90,392 FS 8  
UK Studies        
Browne (2007) [22] Prospective 
cohort 
Orthopaedic  700 EQ5D Index, 
OHS, OKS, SF-36 
8 24-27% 
Coles (2010) [8] Prospective 
cohort 
Orthopaedic NPROMs 29759 EQ5D Index, 
EQ5D VAS, OHS, 
OKS 
16-20 
dependent on 
PROM model 
23-30% 
NHS England 
(2012) [23] 
Retrospective 
cohort 
Orthopaedic NPROMs 282,037 EQ5D Index, 
EQ5D VAS, OHS, 
OKS 
13-15 
dependent on 
tool (some 
variable items  
listed & coded 
separately) 
 
Gutacker (2012) Retrospective Orthopaedic NPROMs 24,568  EQ5D 7  
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[25] cohort 
NHS England 
(2013) [24] 
Retrospective 
cohort 
Orthopaedic NPROMs 282,037 (as for NHS 
England, 2012) 
EQ5D Index, 
EQ5D VAS, OHS, 
OKS 
12 (some 
variable items  
listed & coded 
separately) 
 
Nuttall (2015) [26] Retrospective 
cohort 
Orthopaedic NPROMs 30,555  OKS 10 (some 
variable items 
listed & coded 
separately) 
26% (OLS and FE 
model) 
OHSM; Overall health status measure, SF-12; Short Form 12, SF-36; Short Form 36, FS; Functional Status, PM; psychological measure, BM; baseline model, 
OLS; ordinary least squares, FE; fixed effects, OKS; Oxford Knee Score, OHS; Oxford Hip Score.   
17 
 
Table 3: Summary of Risk-Adjustment Model Variables 
  Base
lin
e
 P
R
O
M
 sco
re 
A
ge 
G
e
n
d
e
r 
C
o
m
o
rb
id
itie
s 
D
u
ratio
n
 o
f sym
p
to
m
s 
Su
rgical h
isto
ry 
P
aye
r 
Im
p
airm
e
n
t typ
e
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d
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d
e
x o
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u
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e
p
rivatio
n
 
Exercise
 H
isto
ry 
Eth
n
icity 
A
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ce
 w
ith
 q
u
e
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n
n
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D
isab
ility 
Livin
g alo
n
e
 
Fear A
vo
id
an
ce B
elie
fs 
Q
u
e
stio
n
n
aire 
U
se
 o
f m
e
d
icatio
n
 
First Author/s US                                 
Resnik 2003 [18] x* x x   x* x x*     x             
Hart and Connolly 2006 [6] x* x* x   x* x x x   x           x 
Hart 2011 [5] x* x x x* x* x x               x   
Hart 2011 [17] x* x x x* x x* x*     x         x x 
Resnik 2011 [18] x x x x x   x     x             
Yen 2015 [19] x x x x x x x                   
Gozalo 2016 [21] x* x x x* x* x x* x             x   
Werneke 2016 [20] x* x* x x* x* x* x*     x           x 
First Author/s UK                                 
Browne 2007 [22] x* x* x x* x x*     x*               
Coles 2010 [8] x* x x x* x x   x x*    x x x* x     
NHS England 2012 [23] x* x x x x x   x x*    x x* x* x     
NHS England 2013 [24] x* x* x* x*  x     x* x*    x* x* x* x     
Gutacker 2012 [25] x x x* x*   x*   x* x*                
Nuttall 2015 [26] x x x x   x   x x   x x x       
Note: only variables used in 3 or more studies are included, * marks those identified in studies as most predictive variables 
   Resnik et al  (2003) * 3 largest predictors 
              
18 
 
Hart and Connolly (2006) * 3 largest predictors 
             Hart et al (2011) * 3 largest predictors 
              Hart et al (2011) * 4 largest predictors 
              Resnik et al (2011) baseline model 
               Yen et al (2015) baseline model (all variables predictive) 
            Gozalo et al (2016) * 4 largest predictors 
              Werneke et al (2016) * 6 significant 'patient factor' predictors (retained in model) 
         Browne et al (2007) * 5 largest predictors (not including GH) 
           Coles (2010) * 4 largest predictors across models (not including GH) 
           NHS England (2012) * 4 most predictive across models (not including depression) 
         NHS England (2013) * 9 variables retained across primary hip/knee models 
          Gutacker et al (2012) * 5 largest predictors 
              Nuttall et al (2015) 10 significant variables included in model (not including length of stay) 
         
 
 
 
 
 
19 
 
Ethical Approval: Not applicable 
Funding: Not applicable 
Conflict of Interest: This is to confirm that co-author Annette Bishop is an Editor for Physiotherapy 
but was not involved with the peer review of the paper or the final decision.  
 
References 
[1] Black N. Patient reported outcome measures could help transform healthcare. BMJ: British 
Medical Journal (Online). 2013;346.  
[2] NHS England. Bite-size guide to patient insight: The National Patient Reported Outcome 
Measures PROMS Programme. 2016. Available from: https://www.england.nhs.uk/wp-
content/uploads/2018/08/proms-guide-aug-18-v3.pdf 
 [3] Iezzoni LI. 3. 1 Risk adjustment for performance measurement. Performance Measurement for 
Health System Improvement: Experiences, Challenges and Prospects. 2009:251. 
[4] Vasseljen O, Woodhouse A, Bjørngaard JH, Leivseth L. Natural course of acute neck and low back 
pain in the general population: the HUNT study. PAIN®. 2013 Aug 31;154(8):1237-44. 
[5] Hart DL, Werneke MW, Deutscher D, George SZ, Stratford PW. Effect of fear-avoidance beliefs of 
physical activities on a model that predicts risk-adjusted functional status outcomes in patients 
treated for a lumbar spine dysfunction. journal of orthopaedic & sports physical therapy. 2011 
May;41(5):336-45. 
[6] Hart DL, Connolly JB. Pay-for-performance for physical therapy and occupational therapy: 
Medicare Part B Services. Final report. Grant. 2006 Jun 1:9-01.  
[7] Werneke M, Hart DL. Centralization phenomenon as a prognostic factor for chronic low back pain 
and disability. Spine. 2001 Apr 1;26(7):758-64. 
[8] Coles J. PROMs risk adjustment methodology guide for general surgery and orthopaedic 
procedures. Northgate Information Solutions (UK) Ltd. 2010. Available from: 
https://www.england.nhs.uk/statistics/wp-content/uploads/sites/2/2013/07/proms-ris-adj-meth-
sur-orth.pdf    
[9] Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. 
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 
statement. Systematic reviews. 2015 Jan 1;4(1):1. 
 [10] Focus on Therapeutic Outcomes Inc. 2018 [cited August 2018] Available from: 
https://www.fotoinc.com/about-foto  
[11] Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.1.0:130 [updated March 2011]. The Cochrane Collaboration, 2011. Available 
from: www.handbook.cochrane.org. 
20 
 
[12] Department of Health [Accessed May 2017] Available from: 
https://www.gov.uk/government/publications?departments%5B%5D=department-of-health  
[13] NICE [Accessed May 2017] Available from: www.evidence.nhs.uk  
[14] Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening 
the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting 
observational studies. PLoS Med2007;4:e296. 
[15] Critical Appraisal Skills Programme. CASP (Cohort Study) Checklist. 2017. [online] Available from: 
http://docs.wixstatic.com/ugd/dded87_5ad0ece77a3f4fc9bcd3665a7d1fa91f.pdf  
[16] Resnik L, Hart DL. Using clinical outcomes to identify expert physical therapists. Physical 
Therapy. 2003 Nov 1;83(11):990-1002. 
[17] Hart DL, Werneke MW, Deutscher D, George SZ, Stratford PW, Mioduski JE. Using intake and 
change in multiple psychosocial measures to predict functional status outcomes in people with 
lumbar spine syndromes: a preliminary analysis. Physical therapy. 2011 Dec 1;91(12):1812-25. 
[18] Resnik L, Gozalo P, Hart DL. Weighted index explained more variance in physical function than 
an additively scored functional comorbidity scale. Journal of clinical epidemiology. 2011 Mar 
31;64(3):320-30. 
[19] Yen SC, Corkery MB, Chui KK, Manjourides J, Wang YC, Resnik LJ. Risk adjustment for lumbar 
dysfunction: comparison of linear mixed models with and without inclusion of between-clinic 
variation as a random effect. Physical therapy. 2015 Dec 1;95(12):1692-702. 
[20] Werneke MW, Edmond S, Deutscher D, Ward J, Grigsby D, Young M, McGill T, McClenahan B, 
Weinberg J, Davidow AL. Effect of adding McKenzie syndrome, centralization, directional preference, 
and psychosocial classification variables to a risk-adjusted model predicting functional status 
outcomes for patients with lumbar impairments. journal of orthopaedic & sports physical therapy. 
2016 Sep;46(9):726-41. 
[21] Gozalo PL, Resnik LJ, Silver B. Benchmarking outpatient rehabilitation clinics using functional 
status outcomes. Health services research. 2016 Apr 1;51(2):768-89. 
[22] Browne J, Jamieson L, Lewsey J, van der Meulen J, Black N, Cairns J, Lamping D, Smith S, Copley 
L, Horrocks J. Patient Reported Outcome Measures (PROMs) in elective surgery-report to the 
department of health. Health Services Research Unit, London School of Hygiene & Tropical Medicine 
& Clinical Effectiveness Unit, Royal College of Surgeons of England. 2007. 
[23] NHS England. PROMs in England; the case-mix adjustment methodology. 2012. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216507/dh_13344
9.pdf  
[24] NHS England. Patient reported outcome measures in England: Update to reporting and case-mix 
adjusting hip and knee procedure data. 2013. Available from: 
https://www.england.nhs.uk/statistics/wp-content/uploads/sites/2/2013/10/proms-meth-prim-
revis.pdf 
21 
 
[25] Gutacker, N. Bojke, C. Daidone, S. Devlin, N. & Street, A. Analysing hospital variation in health 
outcome at the level of EQ-5D dimensions. CHE Research Paper, no. 74, Centre for Health 
Economics, University of York, York, UK. 2012. 
[26] Nuttall D, Parkin D, Devlin N. Inter‐provider comparison of patient‐reported outcomes: 
developing an adjustment to account for differences in patient case mix. Health economics. 2015 Jan 
1;24(1):41-54. 
[27] Gomes, M., Gutacker, N., Bojke, C. and Street, A., Addressing missing data in patient-reported 
outcome measures (PROMs): implications for comparing provider performance (No. 101cherp). 
Centre for Health Economics, University of York. 2014. 
[28] Whittle R, Royle KL, Jordan KP, Riley RD, Mallen CD, Peat G. Prognosis research ideally should 
measure time-varying predictors at their intended moment of use. Diagnostic and Prognostic 
Research. 2017 Dec;1(1):1. 
[29] Ware, John & Snow, Kk & MA, Kosinski & BG, Gandek. SF36 Health Survey: Manual and 
Interpretation Guide. Lincoln, RI: Quality Metric, Inc, 1993. 30.  
[30] HSCIC. Finalised Patient Reported Outcome Measures (PROMs) in England: April 2012 to March 
2013. 2014. Available from: https://www.gov.uk/government/statistics/patient-reported-outcome-
measures-proms-in-england-finalised-april-2012-to-march-2013  
[31] NHS England. Patent Reported Outcome Measures (PROMs) An alternative aggregation 
methodology for case-mix adjustment. 2013. Available from: 
http://www.england.nhs.uk/statistics/wp-content/uploads/sites/2/2013/07/proms-agg-meth-
adju.pdf   
[32] Petrie A, Sabin C. Medical statistics at a glance. John Wiley & Sons; 2013 Nov 8. 84. 
[33] Cohen J. Statistical power analysis for the behavioral sciences. 2nd. 79-82. 
[34] Burstin HR, Lipsitz SR, Brennan TA. Socioeconomic status and risk for substandard medical care. 
Jama. 1992 Nov 4;268(17):2383-7. 
[35] Childs JD, Harman JS, Rodeghero JR, Horn M, George SZ. Implications of practice setting on 
clinical outcomes and efficiency of care in the delivery of physical therapy services. journal of 
orthopaedic & sports physical therapy. 2014 Dec;44(12):955-63. 
[36] Deutscher D, Werneke MW, Gottlieb D, Fritz JM, Resnik L. Physical therapists' level of McKenzie 
education, functional outcomes, and utilization in patients with low back pain. journal of 
orthopaedic & sports physical therapy. 2014 Dec;44(12):925-36. 
[37] Judge A, Javaid MK, Arden NK, Cushnaghan J, Reading I, Croft P, Dieppe PA, Cooper C. Clinical 
tool to identify patients who are most likely to achieve long‐term improvement in physical function 
after total hip arthroplasty. Arthritis care & research. 2012 Jun;64(6):881-9.  
[38] Resnik L, Liu D, Mor V, Hart DL. Predictors of physical therapy clinic performance in the 
treatment of patients with low back pain syndromes. Physical therapy. 2008 Sep 1;88(9):989-1004.  
22 
 
[39] Rodeghero JR, Cook CE, Cleland JA, Mintken PE. Risk stratification of patients with low back pain 
seen in physical therapy practice. Manual therapy. 2015 Dec 1;20(6):855-60. 
[40] Schäfer T, Krummenauer F, Mettelsiefen J, Kirschner S, Günther KP. Social, educational, and 
occupational predictors of total hip replacement outcome. Osteoarthritis and cartilage. 2010 Aug 
1;18(8):1036-42. 
[41] Werneke MW, Hart DL, Resnik L, Stratford PW, Reyes A. Centralization: prevalence and effect on 
treatment outcomes using a standardized operational definition and measurement method. journal 
of orthopaedic & sports physical therapy. 2008 Mar;38(3):116-25. 
[42] Werneke MW, Hart DL, George SZ, Stratford PW, Matheson JW, Reyes A. Clinical outcomes for 
patients classified by fear-avoidance beliefs and centralization phenomenon. Archives of physical 
medicine and rehabilitation. 2009 May 1;90(5):768-77. 
[43] Werneke MW, Hart DL, George SZ, Deutscher D, Stratford PW. Change in psychosocial distress 
associated with pain and functional status outcomes in patients with lumbar impairments referred 
to physical therapy services. journal of orthopaedic & sports physical therapy. 2011 Dec;41(12):969-
80. 
[44] Werneke MW, Hart DL, Cutrone G, Oliver D, McGill MT, Weinberg J, Grigsby D, Oswald W, Ward 
J. Association between directional preference and centralization in patients with low back pain. 
journal of orthopaedic & sports physical therapy. 2011 Jan;41(1):22-31. 
[45] Braeken AM, Lochhaas-Gerlach JA, Gollish JD, MYĹES JD, Mackenzie TA. Determinants of 6—12 
Month Postoperative Functional Status and Pain After Elective Total Hip Replacement. International 
Journal for Quality in Health Care. 1997 Jan 1;9(6):413-8. 
[46] Fanuele JC, Birkmeyer NJ, Abdu WA, Tosteson TD, Weinstein JN. The impact of spinal problems 
on the health status of patients: have we underestimated the effect?. Spine. 2000 Jun 
15;25(12):1509-14.  
[47] Grigsby J, Kaye K, Kowalsky J, Kramer AM. Relationship between functional status and the 
capacity to regulate behavior among elderly persons following hip fracture. Rehabilitation 
Psychology. 2002 Aug;47(3):291. 
 
 
 
23 
 
Appendix 1: 
Search Results: 
# Database Search term Results 
1 Medline (physiotherap*).ti,ab 20170 
2 Medline ("physical therap*").ti,ab 17332 
3 Medline (rheumatolog*).ti,ab 27857 
4 Medline (Orthopaedi*).ti,ab 32882 
5 Medline (Orthopedi*).ti,ab 35796 
6 Medline (Chiropract*).ti,ab 5047 
7 Medline (Osteopath*).ti,ab 4747 
8 Medline (rehabilitat*).ti,ab 132634 
9 Medline exp "PHYSICAL THERAPY 
MODALITIES"/ 
198318 
10 Medline REHABILITATION/ 189286 
11 Medline exp "MUSCULOSKELETAL 
MANIPULATIONS"/ 
14266 
12 Medline (1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 
8 OR 9 OR 10 OR 11) 
539790 
13 Medline (low* ADJ back).ti,ab 27483 
14 Medline (cervical).ti,ab 184992 
15 Medline (spine).ti,ab 93636 
16 Medline (spinal).ti,ab 225643 
17 Medline (hip).ti,ab 110924 
18 Medline (knee).ti,ab 109237 
19 Medline (shoulder).ti,ab 52204 
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20 Medline (Musculoskeletal).ti,ab 37510 
21 Medline SCIATICA/ 4718 
22 Medline exp "BACK PAIN"/ 32951 
23 Medline exp SPINE/ 124297 
24 Medline HIP/ 10837 
25 Medline exp "HIP JOINT"/ 23967 
26 Medline exp "KNEE JOINT"/ 50054 
27 Medline KNEE/ 12391 
28 Medline SHOULDER/ 11036 
29 Medline "SHOULDER JOINT"/ 16237 
30 Medline SHOULDER/ 11036 
31 Medline exp "MUSCULOSKELETAL PAIN"/ 2627 
32 Medline exp "MUSCULOSKELETAL SYSTEM"/ 1336749 
33 Medline exp "MUSCULOSKELETAL DISEASES"/ 988774 
34 Medline (13 OR 14 OR 15 OR 16 OR 17 OR 18 
OR 19 OR 20 OR 21 OR 22 OR 23 OR 
24 OR 25 OR 26 OR 27 OR 28 OR 29 
OR 30 OR 31 OR 32 OR 33) 
2410888 
35 Medline (Baseline variabl*).ti,ab 36869 
36 Medline (Characteristic*).ti,ab 1080307 
37 Medline (demographic*).ti,ab 218641 
38 Medline (prognostic indicat*).ti,ab 40056 
39 Medline (predictor*).ti,ab 280753 
40 Medline exp "POPULATION 
CHARACTERISTICS"/ 
7252956 
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41 Medline FORECASTING/ 76553 
42 Medline (35 OR 36 OR 37 OR 38 OR 39 OR 40 
OR 41) 
8067345 
43 Medline (Patient Recorded Outcome 
Measure*).ti,ab 
2458 
44 Medline (PROM).ti,ab 1835 
45 Medline (effectiveness).ti,ab 337302 
46 Medline ("Change score*").ti,ab 2984 
47 Medline ("Health gain*").ti,ab 1399 
48 Medline ("Functional status*").ti,ab 20277 
49 Medline (43 OR 44 OR 45 OR 46 OR 47 OR 48) 364094 
50 Medline (case mix adjustment).ti,ab 946 
51 Medline (case-mix adjustment).ti,ab 934 
52 Medline ("risk adjust*").ti,ab 6856 
53 Medline ("regression analys*").ti,ab 200297 
54 Medline "RISK ADJUSTMENT"/ 2594 
55 Medline exp "REGRESSION ANALYSIS"/ 347144 
56 Medline (50 OR 51 OR 52 OR 53 OR 54 OR 55) 489201 
57 Medline (12 AND 34 AND 42 AND 49 AND 56) 401 
58 Medline (12 AND 34 AND 49 AND 56) 425 
59 Medline (mortalit*).ti,ab 578260 
60 Medline (random* ADJ2 trial*).ti,ab 253649 
61 Medline (59 OR 60) 804076 
62 Medline 57 NOT 61 293 
26 
 
63 Medline 58 NOT 61 313 
64 Medline 62 [DT 1992-2017] [Human age 
groups Young adult OR Adult OR 
Middle Aged OR Aged OR Aged,80 
and over] [Languages English] 
246 
65 Medline 63 [DT 1992-2017] [Human age 
groups Young adult OR Adult OR 
Middle Aged OR Aged OR Aged,80 
and over] [Languages English] 
252 
 
 
 
